Conclusions: Calls to action for improving the life of MS patients and their families

Abstract

Background:

The first and second Pan-European MS Multi-stakeholder Colloquia were set up to increase cross-talk and communication between the different stakeholders in MS and developed joint Calls to Action to improve (equal) access to quality care and treatment for MS in Europe.

Objective & Methods:

To summarise the 10 integrated and interrelated Calls to Action developed.

Results & Conclusion:

Call 1: increase awareness in the European community about the burden MS places on patients, caregivers and society. Call 2: improve communication towards the European community on the direct and indirect cost burden of MS. Call 3: perform patient research to (re)define treatment goals/endpoints from a humanistic/patient perspective point of view. Call 4: develop new tools to better capture the total clinical burden of MS. Call 5: develop a protocol for standardisation of MRI for optimising its use as a marker of disability progression in MS. Call 6: support research to find other (molecular) biomarkers which can predict long-term disability progression and (monitor) individual treatment response. Call 7: align CHMP/EMA and HTA decision-making process. Call 8: develop separate EMA guidelines for evaluating follow-on products of non-biological complex drugs. Call 9: support people with MS remaining (physically) active and at work and stimulate the implementation of specialised care centres. Call 10: support the continuation of multi-stakeholder colloquia.

Keywords

Multiple sclerosis multi-stakeholders patient clinician payer regulator

Get full access to this article

View all access options for this article.

References

The first Pan-European multiple sclerosis multi-stakeholder colloquium: Exploring opportunities and challenges for improving multiple sclerosis management (agenda), http://2014.ms-colloquium.org/programme (2014, accessed 3 December 2015).

Vermersch

Smets

. Introduction: Do we need multi-stakeholder colloquia in MS? Mult Scler 2016; S2: 4–8.

The Pan-European multiple sclerosis multi-stakeholder colloquia (calls to action), https://dl.dropboxusercontent.com/u/7697080/MS%20Colloquium%202015/Calll_to_action2015.pdf (2015, accessed 3 December 2015).

The second Pan-European multiple sclerosis multi-stakeholder colloquium: Accelerating adoption of innovation for better care (agenda), http://ms-colloquium.org/programme (2015, accessed 3 December 2015).

Vermersch

Faller

Czarnota-Szałkowska

. The patient’s perspective: How to create awareness for improving access to care and treatment of MS patients? Mult Scler 2016; S2: 9–17.

Vermersch

Berger

Gold

. The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? Mult Scler 2016; S2: 18–33.

Feys

Giovannoni

Dijsselbloem

. The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Mult Scler 2016; S2: 34–46.

Crommelin

DJA

Broich

Holloway

. The regulator’s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future? Mult Scler 2016; S2: 47–59.

Gold

Toumi

Meesen

. The payer’s perspective: What is the burden of MS and how should the patient’s perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment? Mult Scler 2016; S2: 60–70.

10.

Rovira

Wattjes

Tintoré

. MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis – Clinical implementation in the diagnostic process. Nat Rev Neurol 2015; 11: 471–482.

11.

Motl

. Lifestyle physical activity in persons with multiple sclerosis: The new kid on the MS block. Mult Scler 2014; 20: 1025–1029.